SecSonar.com

Becton, Dickinson and Company (BDX)

Becton, Dickinson and Company at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Becton, Dickinson and Company (BDX) is a Medical - Instruments & Supplies company based in US with a market capitalization of $53.8B. Revenue grew 8.2% year-over-year and the company generated $2.7B in free cash flow. This page tracks BDX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 70K employees · IPO Feb 21, 1973

Valuation

Valuation & price

$143.47 · as of May 17, 2026 · -22.6% vs 52w high

24.5

P/E ratio

Latest-FY diluted EPS

2.12

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$185$160$136Jul 25Dec 25Jul 26Jul 7, 25$135.97Jul 9, 25$137.97Jul 11, 25$138.34Jul 15, 25$140.18Jul 17, 25$142.22Jul 21, 25$137.84Jul 23, 25$143.54Jul 25, 25$145.69Jul 29, 25$143.38Jul 31, 25$140.13Aug 4, 25$140.64Aug 6, 25$135.54Aug 11, 25$151.34Aug 13, 25$154.06Aug 15, 25$154.04Aug 19, 25$155.68Aug 21, 25$154.58Aug 25, 25$153.03Aug 27, 25$153.62Aug 29, 25$151.71Sep 3, 25$149.06Sep 5, 25$151.25Sep 9, 25$149.76Sep 11, 25$149.81Sep 16, 25$146.39Sep 18, 25$148.09Sep 22, 25$146.66Sep 24, 25$146.27Sep 26, 25$145.13Sep 30, 25$147.15Oct 2, 25$150.63Oct 6, 25$150.94Oct 8, 25$152.46Oct 10, 25$146.67Oct 14, 25$148.08Oct 16, 25$145.65Oct 21, 25$148.61Oct 23, 25$146.64Oct 27, 25$147.04Oct 29, 25$142.70Oct 31, 25$140.50Nov 4, 25$140.75Nov 6, 25$139.46Nov 10, 25$142.80Nov 12, 25$151.04Nov 14, 25$151.76Nov 18, 25$151.20Nov 20, 25$149.04Nov 25, 25$153.69Nov 28, 25$152.53Dec 2, 25$149.74Dec 4, 25$152.33Dec 8, 25$148.98Dec 10, 25$155.97Dec 12, 25$157.93Dec 16, 25$154.39Dec 18, 25$153.07Dec 22, 25$154.67Dec 24, 25$154.18Dec 29, 25$153.43Jan 2, 26$153.25Jan 6, 26$161.45Jan 8, 26$161.31Jan 12, 26$159.39Jan 14, 26$163.07Jan 16, 26$162.82Jan 21, 26$162.09Jan 23, 26$158.64Jan 27, 26$159.91Jan 29, 26$158.09Feb 2, 26$158.73Feb 4, 26$163.42Feb 9, 26$163.04Feb 11, 26$180.62Feb 13, 26$175.89Feb 18, 26$182.68Feb 20, 26$185.39Feb 24, 26$182.49Feb 26, 26$176.66Mar 2, 26$176.54Mar 4, 26$171.49Mar 6, 26$167.12Mar 10, 26$163.88Mar 12, 26$159.63Mar 17, 26$161.64Mar 19, 26$156.53Mar 23, 26$156.23Mar 25, 26$158.27Mar 27, 26$154.51Mar 31, 26$157.23Apr 2, 26$154.51Apr 7, 26$154.96Apr 9, 26$155.46Apr 13, 26$155.43Apr 15, 26$155.52Apr 17, 26$158.54Apr 22, 26$155.65Apr 24, 26$152.14Apr 28, 26$149.52Apr 30, 26$149.04May 4, 26$146.31May 6, 26$144.76May 8, 26$149.43May 12, 26$147.51May 14, 26$144.47May 18, 26$142.35May 20, 26$146.95May 22, 26$147.63May 28, 26$148.41Jun 1, 26$145.33Jun 3, 26$145.61Jun 5, 26$151.16Jun 9, 26$152.04Jun 11, 26$147.35Jun 15, 26$145.52Jun 17, 26$141.61Jun 22, 26$140.71Jun 24, 26$147.77Jun 26, 26$155.92Jul 2, 26$155.31
$135.5452-week range$185.39
Loading valuation history…

Fundamentals

Key fundamentals

$53.8B

Market cap

8.2%

Revenue growth (YoY)

45.4%

Gross margin

$2.7B

Free cash flow (USD)

$18.3B

Net debt

-1.1%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$12.5BFY 2017$12.1BFY 2018$16.0BFY 2019$17.3BFY 2020$16.1BFY 2021$19.1BFY 2022$18.9BFY 2023$19.4BFY 2024$20.2BFY 2025$21.8B
$12.5B$21.8B

Free cash flow by year

2016 → 2025

FY 2016$1.8BFY 2017$1.8BFY 2018$2.0BFY 2019$2.4BFY 2020$2.7BFY 2021$3.4BFY 2022$1.7BFY 2023$2.1BFY 2024$3.1BFY 2025$2.7B
$1.8B$2.7B

Gross margin by year

2021 → 2025

FY 202145.1%FY 202244.9%FY 202342.2%FY 202445.2%FY 202545.4%
45.1%45.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

6

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $11KFeld Michael · EVP, Chief Revenue Officer · $11.5KJun 26, 2026Filing
  • Insider sellInsider Sell $160KGarrison Michael David · EVP & Pres Med.Essntl&BioPharm · $160.2KJun 25, 2026Filing
  • Insider sellInsider Sell $167KGarrison Michael David · EVP & Pres Med.Essntl&BioPharm · $166.6KJun 11, 2026Filing
  • Insider sellInsider Sell $405KPolen Thomas E Jr · Director, Chairman, CEO and President · $404.5KJun 3, 2026Filing
  • 8-K eventProduct Shipment ResumedMay 29, 2026Filing
  • Insider sellInsider Sell $11KFeld Michael · EVP, Chief Revenue Officer · $11.1KMay 27, 2026Filing
  • 8-K eventDebt IssuanceMay 20, 2026Filing
  • 8-K eventDebt Securities IssuanceMay 12, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • 8-K eventCFO AppointmentMay 7, 2026Filing

Questions

Frequently asked questions

What is Becton, Dickinson and Company's market cap?

Becton, Dickinson and Company (BDX) has a market capitalization of $53.8B.

What is BDX's P/E ratio?

BDX trades at a price-to-earnings ratio of 24.5, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is BDX's price-to-book (P/B) ratio?

BDX trades at 2.12 times book value per share.

Are insiders buying BDX stock?

SEC Form 4 filings show no open-market insider buys at Becton, Dickinson and Company in the last 90 days (6 sells).

Same arena

Related companies in Medical - Instruments & Supplies

ALC

Alcon Inc.

$32.5B

MDLN

Medline Inc.

$31.2B

WST

West Pharmaceutical Services, Inc.

$22.6B

COO

The Cooper Companies, Inc.

$12B

BAX

Baxter International Inc.

$9.8B

ATR

AptarGroup, Inc.

$7.4B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.